Citations

Clear

959 citation(s) found for "Service, F J".

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
Villa, Diego , Visco, Carlo , Crosbie, Nicola, McCulloch, Rory , Buege, Michael J. , Kumar, Anita , Bond, David A. , Maurer, Matthew J. , Thanarajasingam, Gita , Lewis, Katharine L. , Cheah, Chan Y. , Bæch, Joachim , Kugathasan, Laveniya , Lewis, David , Visco, Carlo , McCulloch, Rory , Buege, Michael J , Kumar, Anita , Bond, David A , Paludo, Jonas , Maurer, Matthew , Lewis, Katharine L , Cheah, Chan Yoon , Baech, Joachim , El-Galaly, Tarec C , Scott, David W , Gerrie, Alina S , Jiang, Aixiang , Paludo, Jonas , El‐Galaly, Tarec Christoffer , Scott, David W. , Gerrie, Alina S.

Mayo Clinic

Blood Advances | June 12, 2023 | Volume: 7 | Issue: 16 | Pages: 4576-4585

10.1182/bloodadvances.2023009804 | PMID 37307169 Get It

Abstract Time to progression of disease (POD) after first-line (1L) therapy is prognostic in mantle cell lymphoma (MCL), although studies have included a broad range of 1L, second-line (2L), and subsequent lines of therapy. The purpose of this study was to evaluate the factors predicting outcomes in patients with relapsed/refractory (R/R) MCL exclusively initiating 2L Bruton’s tyrosine kinase inhibitors (BTKis) after 1L rituximab-containing therapy. Patients were accrued from 8 international centers (7 main, 1 validation cohort). Multivariable models evaluating the association between time to POD and clinical/pathologic factors were constructed and converted into nomograms and prognostic indexes predicting outcomes in this population. A total of 360 patients were included, including 160 in the main cohort and 200 in the validation cohort. Time to POD, Ki67 ≥ 30%, and MCL International Prognostic Index (MIPI) were associated with progression-free survival (PFS2) and overall survival (OS2) from the start of 2L BTKis. C-indexes were consistently ≥0.68 in both cohorts. Web/application-based calculators based on nomograms and prognostic indexes to estimate PFS2 and OS2 were constructed. The 2L BTKi MIPI identifies 3 groups with distinct 2-year PFS2, including high risk (14%), intermediate risk (50%), and low risk (64%). Time to POD, Ki67, and MIPI are associated with survival outcomes in patients with R/R MCL receiving 2L BTKis. Simple clinical models incorporating these variables may assist in planning for alternative therapies such as chimeric antigen receptor T-cell therapy, allogeneic stem cell transplantation, or novel agents with alternative mechanisms of action.
Abstract 5229: Pathogenic germline mutations and risk of multiple myeloma
Conry, Michael , Camp, Nicola J. , Vachon, Celine M. , Brown, Elizabeth E. , Lipkin, Steven M. , Stokes, Samantha , Izhar, Aalin , Dandiker, Sita , Offit, Kenneth , Izhar, Aalin , Vachon, Celine M. , Hildebrandt, Michelle A.T. , Garber, Judy E. , Slager, Susan L. , Norman, Aaron D. , Maclachlan, Kylee , Usmani, Saad Z. , Vijai, Joseph

Mayo Clinic

Cancer Research | June 9, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 5229-5229

10.1158/1538-7445.am2023-5229 Get It

Abstract BACKGROUND: Multiple Myeloma (MM) is an incurable disease with no known germline high penetrant risk gene. The higher risk of MM among affected relatives suggests a genetic contribution to the etiology. To date, 24 common risk variants with low effect sizes were identified using genome-wide association studies, which account for 17% of heritability. However, a systematic analysis of the known rare alleles in cancer predisposition genes has not been undertaken so far in MM. We collaborated with six other academic centers across the United States to identify and select cases for analysis of germline predisposition of MM. METHODS: We performed whole exome, next-generation sequencing of 2,387 familial or early onset germline MM cases from the myeloma sequencing consortium (MMSEQ). We called 1.5 million variants and performed standard quality control of the data. We also obtained exome data on 1,285 cases from UK Biobank (UKBB) and 344,513 non-cancer controls (total=3,672 cases). We analyzed the ultra-rare, coding variants in 90 clinically relevant or putative candidates for cancer predisposition. We then used the automated variant curator PathoMAN to annotate and assert pathogenicity of each variant. We contrasted our results with assertions of pathogenicity from ClinVar and tested for gene association with MM. RESULTS: Overall, we observed several pathogenic or likely pathogenic variants, both singleton and recurrent founder mutations. In the MMSEQ, 8.7% of MM cases harbored a pathogenic variant in these known/putative cancer predisposition genes. Predominant group of pathogenic variants were observed within CHEK2 (19%), TP53 (8%), and ATM (5%). A case-control analysis revealed strong association with TP53 and weakly with ATM. In the familial/early onset MMSEQ cases, TP53 mutations were enriched 68 times more than in the UKBB controls. Our preliminary results suggest that known genes of cancer susceptibility such as TP53 and ATM may also play a role in myeloma risk. CONCLUSION: In a large study of multi-center MM cases, we identified a significant proportion of individuals who are carriers of known (solid) cancer predisposition genes. This study suggests that these known cancer predisposition genes may be relevant in a subset of MM cases. Citation Format: Michael T. Conry, Nicola Camp, Celine Vachon, Michelle Hildebrandt, Elizabeth E. Brown, Steven M. Lipkin, Judy Garber, Susan L. Slager, Samantha Stokes, Aaron D. Norman, Aalin Izhar, Sita Dandiker, Kylee Maclachlan, Kenneth Offit, Saad Usmani, Vijai Joseph. Pathogenic germline mutations and risk of multiple myeloma. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5229.
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
Weinshenker, Brian G. , Wingerchuk, Dean M. , Green, Ari , Bennett, Jeffrey L. , Kim, Ho Jin , Pittock, Sean J, Paul, Friedemann , Marignier, Romain , Aktaş, Orhan , She, Dewei, Smith, Michael , Rees, William A. , Patterson, Kristina, Cimbora, Daniel , Katz, Eliezer , Pittock, Sean J. , Kunchok, Amy , Pittock, S J , Green, Ari J , Pittock, Sean J , Marignier, Romain , Cree, Bruce Ac , Bennett, Jeffrey L , Weinshenker, Brian G , Paul, Friedemann , Fujihara, Kazuo , Cutter, Gary , Hartung, Hans‐Peter , Patterson, Kristina R. , Cree, Bruce

Mayo Clinic

Multiple Sclerosis Journal | June 7, 2023 | Volume: 29 | Issue: 8 | Pages: 945-955

10.1177/13524585231172145 | PMID 37282545 Get It

Background: The N-MOmentum trial investigated safety and efficacy of inebilizumab in participants with neuromyelitis optica spectrum disorder (NMOSD). Objective: Evaluate the attack identification process and adjudication committee (AC) performance in N-MOmentum. Methods: Adults ( n = 230) with NMOSD and Expanded Disability Status Scale score ⩽8 were randomized (3:1) to inebilizumab 300 mg or placebo. The randomized controlled period was 28 weeks or until adjudicated attack. Attacks were adjudicated according to 18 predefined criteria. Magnetic resonance imaging (MRI) and biomarker (serum glial fibrillary acidic protein [sGFAP]) analyses were performed. Results: A total of 64 participant-reported neurological events occurred; 51 (80%) were investigator-determined to be attacks. The AC confirmed 43 of the investigator-determined attacks (84%). There was high inter- and intra-AC-member agreement. In 25/64 events (39%) and 14/43 AC-adjudicated attacks (33%), MRI was reviewed during adjudication. Retrospective analysis revealed new domain-specific T1 and T2 MRI lesions in 90% of adjudicated attacks. Increased mean sGFAP concentrations (>2-fold change) from baseline were observed in 56% of adjudicated attacks versus 14% of investigator-determined attacks rejected by the AC and 31% of participant-reported events determined not to be attacks. Conclusion: AC adjudication of NMOSD attacks according to predefined criteria appears robust. MRI lesion correlates and sGFAP elevations were found in most adjudicated attacks.
Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease
McKeown, Pascal , Page, Stephen P, Galvin, Joseph , Petzer, E, Roden, Dan M. , Veltmann, Christian , Aiba, Takeshi , Ackerman, Michael J. , Wijeyeratne, Yanushi D. , Tanck, Michael , Probst, Vincent , Crotti, Lia , Horie, Minoru , Roden, Dan M. , Veltmann, Christian , Makita, Naomasa , Aiba, Takeshi , Behr, Elijah Raphael

Mayo Clinic

Europace | May 24, 2023 | Volume: 25 | Issue: Supplement_1 | Pages: No page available

10.1093/europace/euad122.280 Get It

Abstract Funding Acknowledgements Type of funding sources: Public Institution(s). Main funding source(s): National Institute of Health Research St George's, University of London Background SCN5A-E1784K (c.5350G>A) is the most common variant associated with the LQT3 long QT syndrome (LQTS) and Brugada syndrome (BrS). It exhibits incomplete penetrance and can manifest variably as a mixed clinical phenotype of LQTS, BrS and/or conduction disorders (1-4). This presents a challenge for risk stratification and optimal management. We aimed to describe the clinical characteristics and risk markers in a large, well characterised international cohort of SCN5A-E1784K subjects and identify demographic and/or ECG parameters associated with event free survival. Methods Comprehensive clinical data, including initial presentation and follow-up data, were collected from SCN5A-E1784K subjects. Outcome ‘events’ included sudden death, aborted cardiac arrest, and documented VF or VT or arrhythmic syncope. ‘Lethal events’ included sudden death, aborted cardiac arrest or documented VF or VT. Associations between clinical characteristics and event free survival were investigated using Cox proportional hazard regression models. Results SCN5A-E1784K subjects (n=231) were recruited from 16 centres. Median follow up was 24.9 years (15.2 - 43.3) and 45 individuals (19%) experienced an event. Lethal events were observed in 14 subjects (6%). Figure 1 shows event (A) and lethal event (B) free survival in SCN5A-E1784K subjects. Higher QRS duration (corrected for age) was associated with shorter event-free interval. QRS duration was the only characteristic associated with increased risk with a hazard ratio (HR) of 1.04 or 1.05 per ms for events and lethal events, respectively. The observed survival for events and lethal events for QRS tertiles are shown in Figure 2. Discussion Ventricular myocardial conduction, as evidenced by QRS duration, appears to play a role in the risk of arrhythmic events in patients with SCN5A-E1784K. Corrected QT interval and BrS phenotype were, however, not associated with risk. This provides an important opportunity for the personalisation of risk stratification of these patients, whose management can otherwise be very challenging. Figures
Voltage-Guided Ablation for Atrial Fibrillation -- Current Insights and Future Directions
Valli, Haseeb , Deshmukh, Abhishek , Nanthakumar, Kumaraswamy , Wong, Tom , Haldar, Shouvik

Mayo Clinic

No container title available | May 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.168483251.13504722/v1 Get It

The prevalence of atrial fibrillation (AF) is forecasted to increase manifold, emphasizing the need for efficacious treatments. Pulmonary vein isolation (PVI) to eliminate ectopic triggers is now established as a fundamental component of the invasive treatment of AF, however its efficacy in persistent AF remains suboptimal. The atrial myocardium undergoes adverse fibrotic remodeling as AF progresses, favoring arrhythmia initiation and maintenance. Reductions in left atrial bipolar voltage have been suggested to identify regions of such pathological remodeling, and represent novel targets for ablation to target the arrhythmogenic substrate. Early observational studies targeting these low voltage areas (LVA) have been encouraging, however results from more recent randomized trials are more mixed. Importantly, there is significant heterogeneity in the techniques for identifying LVAs and the strategies for ablation. In reality, the atrial arrhythmogenic substrate is multi-faceted rather than being limited to fibrosis and there remains uncertainty as to how accurately LVAs represent regions of fibrosis. Additionally, bipolar voltage is influenced by numerous physiological and biophysical factors. The present review summarizes the current evidence for LVA ablation in AF. We then analyze the components of the atrial arrhythmic substrate, its relationship to LVAs and the limitations in LVA assessment. Finally we discuss novel techniques for delineating the atrial substrate.
Subepicardial Cardiomyopathy: A Disease Underlying J-Wave Syndromes and Idiopathic Ventricular Fibrillation
Boukens, Bastiaan J. , Scrocco, Chiara , Wilde, Arthur A.M. , Nademanee, Koonlawee , Haı̈ssaguerre, Michel , Behr, Elijah R. , Miles, Chris , Scrocco, Chiara , Wilde, Arthur A M , Nademanee, Koonlawee , Haissaguerre, Michel , Behr, Elijah Raphael , Coronel, Ruben

Mayo Clinic

Circulation | May 22, 2023 | Volume: 147 | Issue: 21 | Pages: 1622-1633

10.1161/circulationaha.122.061924 | PMID 37216437 Get It

Brugada syndrome (BrS), early repolarization syndrome (ERS), and idiopathic ventricular fibrillation (iVF) have long been considered primary electrical disorders associated with malignant ventricular arrhythmia and sudden cardiac death. However, recent studies have revealed the presence of subtle microstructural abnormalities of the extracellular matrix in some cases of BrS, ERS, and iVF, particularly within right ventricular subepicardial myocardium. Substrate-based ablation within this region has been shown to ameliorate the electrocardiographic phenotype and to reduce arrhythmia frequency in BrS. Patients with ERS and iVF may also exhibit low-voltage and fractionated electrograms in the ventricular subepicardial myocardium, which can be treated with ablation. A significant proportion of patients with BrS and ERS, as well as some iVF survivors, harbor pathogenic variants in the voltage-gated sodium channel gene, SCN5A , but the majority of genetic susceptibility of these disorders is likely to be polygenic. Here, we postulate that BrS, ERS, and iVF may form part of a spectrum of subtle subepicardial cardiomyopathy. We propose that impaired sodium current, along with genetic and environmental susceptibility, precipitates a reduction in epicardial conduction reserve, facilitating current-to-load mismatch at sites of structural discontinuity, giving rise to electrocardiographic changes and the arrhythmogenic substrate.
Plain Language Summary of the MAIA Study of Daratumumab Plus Lenalidomide and Dexamethasone for the Treatment of People with Newly Diagnosed Multiple Myeloma
Kumar, Shaji , Plesner, Torben , Orlowski, Robert Z. , Hulin, Cyrille , Goldschmidt, Hartmut , Macro, Margaret , Leleu, Xavier , Wang, Jianping , Rampelbergh, Rian Van , Uhlar, Clarissa, Vermeulen, Jessica, Duran, Joana , Borgsten, Fredrik, Usmani, Saad Z. , Orlowski, Robert Z. , Usmani, Saad , Facon, Thierry T.F. , Moreau, Philippe , Bahlis, Nizar Jacques , Basu, Supratik , Nahi, Hareth , Quach, Hang , Perrot, Aurore , Weisel, Katja C , Raje, Noopur , Frenzel, Laurent

Mayo Clinic

Future Oncology | May 22, 2023 | Volume: 19 | Issue: 13 | Pages: 887-895

10.2217/fon-2023-0082 | PMID 37212642 Get It

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Wang, Michael , Jurczak, Wojciech , Zinzani, Pier Luigi , Eyre, Toby A. , Cheah, Chan Y. , Ujjani, Chaitra S. , Koh, Youngil , Izutsu, Koji , Gerson, James N. , Flinn, Ian W. , Alencar, Alvaro J. , Ma, Shuo , Lewis, David , Patel, Krish , Maddocks, Kami J. , Lamanna, Nicole , Nagai, Hirokazu, Hernandez‐Ilizaliturri, Francisco J. , Kumar, Anita , Fenske, Timothy S. , Seymour, John F. , Nair, Binoj C., Tsai, Donald E. , Balbas, Minna, Walgren, Richard A., Abada, Paolo, Wang, Chunxiao , Zhao, Junjie, Mato, Anthony R. , Shah, Nirav N. , Wang, Michael L , Flinn, Ian W , Tessoulin, Benoit , Alencar, Alvaro J , Ma, Shuo , Lewis, David , Lech-Maranda, Ewa , Rhodes, Joanna , Patel, Krish , Lamanna, Nicole , Wang, Yucai , Tam, Constantine S , Munir, Talha , Kumar, Anita , Fenske, Timothy S , Seymour, John F , Zelenetz, Andrew D , Abada, Paolo , Mato, Anthony , Shah, Nirav N , Zinzani, Pier Luigi , Cheah, Chan Yoon , Izutsu, Koji , Jurczak, Wojciech , Lech‐Marańda, Ewa , Rhodes, Joanna , Wang, Yucai , Tam, Constantine S. , Zelenetz, Andrew D.

Mayo Clinic

Journal of Clinical Oncology | May 16, 2023 | Volume: 41 | Issue: 24 | Pages: 3988-3997

10.1200/jco.23.00562 | PMID 37192437 Get It

PURPOSE Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (MCL), a population with poor prognosis. METHODS Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter phase I/II trial (BRUIN; ClinicalTrials.gov identifier: NCT03740529 ). Efficacy was assessed in the first 90 consecutively enrolled patients who met criteria for inclusion in the primary efficacy cohort. The primary end point was overall response rate (ORR). Secondary end points included duration of response (DOR) and safety. RESULTS The median patient age was 70 years (range, 46-87), the median prior lines of therapy was 3 (range, 1-8), 82.2% had discontinued a prior cBTKi because of disease progression, and 77.8% had intermediate- or high-risk simplified MCL International Prognostic Index score. The ORR was 57.8% (95% CI, 46.9 to 68.1), including 20.0% complete responses (n = 18). At a median follow-up of 12 months, the median DOR was 21.6 months (95% CI, 7.5 to not reached). The 6- and 12-month estimated DOR rates were 73.6% and 57.1%, respectively. In the MCL safety cohort (n = 164), the most common treatment-emergent adverse events (TEAEs) were fatigue (29.9%), diarrhea (21.3%), and dyspnea (16.5%). Grade ≥3 TEAEs of hemorrhage (3.7%) and atrial fibrillation/flutter (1.2%) were less common. Only 3% of patients discontinued pirtobrutinib because of a treatment-related adverse event. CONCLUSION Pirtobrutinib is a first-in-class novel noncovalent (reversible) BTKi and the first BTKi of any kind to demonstrate durable efficacy after prior cBTKi therapy in heavily pretreated R/R MCL. Pirtobrutinib was well tolerated with low rates of treatment discontinuation because of toxicity.
Guidelines in the JIMD: Evidence‐based practice for inherited metabolic disease
Rahman, Shamima , Patterson, Marc C. , Peters, Verena , Morava, Éva , Zschocke, Johannes , Baumgartner, Matthias R. , Patterson, Marc , Baumgartner, Matthias , Morava, Eva

Mayo Clinic

Journal of Inherited Metabolic Disease | May 9, 2023 | Volume: 46 | Issue: 4 | Pages: 537-538

10.1002/jimd.12620 | PMID 37157107 Get It

Country-level gender inequality is associated with structural differences in the brains of women and men
Alliende, Luz María , Medel, Vicente , Bethlehem, Richard A. I. , Ringlein, Grace , Arango, Celso , Asmal, Laila , Bellgrove, Mark A. , Bernardo, Miquel , Billeke, Pablo , Bosch‐Bayard, Jorge , Busatto, Geraldo F. , Castro, Mariana N. , Chaim-Avancini, Tiffany , Compte, Albert , Costanzi, Monise , Dazzan, Paola , Fuente‐Sandoval, Camilo de la , Díaz‐Zuluaga, Ana M. , Duran, Fábio , Fittipaldi, Sol , Fornito, Alex , Freimer, Nelson B. , Gadelha, Ary , Gama, Clarissa Severino , Ramesh, Ranjini Garani , García‐Rizo, Clemente , Campo, Cecilia González , González‐Valderrama, Alfonso , Holla, Bharath , Ibáñez, Agustín , Ivanovic, Daniza , Jackowski, Andrea Parolin , Löchner, Christine , López‐Jaramillo, Carlos , Massuda, Raffael , McGuire, Philip , Murray, Robin , Özerdem, Ayşegül , Pan, Pedro Mário , Parellada, Mara , Phahladira, Lebogan, Ramírez-Mahaluf, Juan Pablo , Reyes-Madrigal, Francisco , Roos, Annerine , Scheffler, Freda , Stein, Dan J. , Tepper, Ángeles , Ueno, Tsukasa, Undurraga, Juan , Valli, Isabel , Villarreal, Mirta F. , Yalın, Nefize , Zamorano, Francisco , Zanetti, Marcus V. , cVEDA, Pine, Daniel S. , Evans‐Lacko, Sara , Crossley, Nicolás , Murthy, Pratima , Chakrabarti, Amit , Basu, Debasish , Subodh, B. N., Singh, Lenin, Singh, Roshan Lourembam, Kalyanram, Kartik , Kartik, Kamakshi, Kurpad, Sunita Simon , Bharath, Rose Dawn , Orfanos, Dimitri Papadopoulos , Sharma, Eesha , Alliende, Luz María , Medel, Vicente , Bethlehem, Richard A I , Benegal, Vivek , Bernardo, Miquel , Billeke, Pablo , Busatto, Geraldo F , Castro, Mariana N , Czepielewski, Leticia , de la Fuente-Sandoval, Camilo , Duran, Fabio L S , Fittipaldi, Sol , Fornito, Alex , Garani, Ranjini , Guinjoan, Salvador , Ibañez, Agustín , Ivanovic, Daniza , Lochner, Christine , Massuda, Raffael , Miyata, Jun , Mizrahi, Romina , Murray, Robin , Ramirez-Mahaluf, Juan P , Reis Marques, Tiago , Reyes-Madrigal, Francisco , Roos, Annerine , Salum, Giovanni , Stein, Dan J , Tepper, Angeles , Undurraga, Juan , Undurraga, Eduardo A , Valdes-Sosa, Pedro , Valli, Isabel , Zamorano, Francisco , Crossley, Nicolas A , López-Jaramillo, Carlos , Ozerdem, Aysegul , Yalin, Nefize , Zugman, André , Seidlitz, Jakob , Arnatkevičiūtė, Aurina , Bressan, Rodrigo A. , Forti, Marta Di , Díaz‐Caneja, Covadonga M. , Plessis, Stefan S. du , León-Ortíz, Pablo , Luckhoff, Hilmar Klaus , Phahladira, Lebogang , Reckziegel, Ramiro de Freitas Xavier , Rosa-Neto, Pedro , Serpa, Maurício Henriques , Winton‐Brown, Toby , cVEDA, Winkler, Anderson M. , Kartik, Kamakshi , Kumaran, Kalyanaraman , Krishnaveni, Ghattu Vedamurthy , Kuriyan, Rebecca , Barker, Gareth J. , Desrivières, Sylvane , Purushottam, Meera , Hickman, Matthew , Heron, Jon , Toledano, Mireille B. , Vaidya, Nilakshi

Mayo Clinic

Proceedings of the National Academy of Sciences | May 8, 2023 | Volume: 120 | Issue: 20 | Pages: No page available

10.1073/pnas.2218782120 | PMID 37155867 Get It

Gender inequality across the world has been associated with a higher risk to mental health problems and lower academic achievement in women compared to men. We also know that the brain is shaped by nurturing and adverse socio-environmental experiences. Therefore, unequal exposure to harsher conditions for women compared to men in gender-unequal countries might be reflected in differences in their brain structure, and this could be the neural mechanism partly explaining women’s worse outcomes in gender-unequal countries. We examined this through a random-effects meta-analysis on cortical thickness and surface area differences between adult healthy men and women, including a meta-regression in which country-level gender inequality acted as an explanatory variable for the observed differences. A total of 139 samples from 29 different countries, totaling 7,876 MRI scans, were included. Thickness of the right hemisphere, and particularly the right caudal anterior cingulate, right medial orbitofrontal, and left lateral occipital cortex, presented no differences or even thicker regional cortices in women compared to men in gender-equal countries, reversing to thinner cortices in countries with greater gender inequality. These results point to the potentially hazardous effect of gender inequality on women’s brains and provide initial evidence for neuroscience-informed policies for gender equality.